west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "GAO Sihai" 3 results
  • Expression of CD105 Protein in Esophageal Squamous Cell Carcinoma and It's Relationship with P53 Protein

    Objective To explore the expression of CD105 protein in esophageal squamous cell carcinoma and it's relationship with P53 protein. Methods Using streptavidin biotinperoxidase (SP) method, the expression of CD105 protein and P53 protein in esophageal squamous cell carcinoma were examined in normal esophageal tissues (n=10) and esophageal squamous cell carcinoma tissues(n=86). Results The expression positive rate of CD105 protein was 74. 4%(64/86) in esophageal squamous cell carcinoma , 0% in normal esophageal epithelium. Expression positive rate of CD105 protein was 66. 1%(37/56) in early stage (stage Ⅰ-Ⅱ ), 90.0% (27/30) in later stages (stage Ⅲ-Ⅳ ). The expression of CD105 protein were bly associated with P53 protein(P〈0. 05). Conclusion CD105 protein may participate in the onset and progression of esophageal squamous cell carcinoma. CD105 protein could he a new diagnostic /therapeutic target in esophageal squamous cell carcinoma.

    Release date:2016-08-30 06:26 Export PDF Favorites Scan
  • Effect of Interleukin-10 Gene Transfer on Expression of Cell Adhesion Molecules in Mice Heart Transplantation Rejection

    Objective To investigate the effect of interleukin-10 (IL-10) gene transfer on expression of CD44, selectin-E, lymphocyte function associated antigen-1 (LFA-1), vascular cell adhesion molecule-1 (VCAM-1) in mice heart transplantation rejection. Methods Model of mice cervical heterotopic heart transplantation was set up, 96 mice were divided into three groups with random number table, control group: heart transplantation between C57 mice; transplant group: heart from BALB/C mice transplant to C57 mice; IL-10 group: IL-10 was transfected on BALB/C mice isolated heart for 1 hour, then transplanted to C57 mice. The messenger ribonucleic acid (mRNA) level expression of CD44 ,selectin-E ,LFA-1 ,VCAM-1 and IL-10 were measured by reverse transcription-polymerase chain reaction (RT-PCR) at the 5th day after transplantation. Results The mRNA level expression of CD44, selectin-E ,LFA-1 ,VCAM-1 in transplant group were significantly increased than those in control group (P〈0.01). The mRNA level expression of CD44, selectin-E, LFA-1 ,VCAM-1 in IL-10 group were significantly decreased than those in transplant group (P〈0.01). Conclusion IL-10 gene transfer is able to decrease the expression of CD44, selectin-E,LFA-1 ,VCAM-1 and suppress the heart transplantation rejection in mice.

    Release date:2016-08-30 06:26 Export PDF Favorites Scan
  • Protective effects of metformin on myocardial injury in patients with COVID-19 combined with coronary heart diseases and diabetes

    ObjectiveTo investigate whether metformin has protective effect on myocardial injury in patients with coronavirus disease 2019 (COVID-19) combined with coronary heart diseases and diabetes.MethodsCOVID-19 patients with coronary heart disease and diabetes who were admitted to Tongji Hospital from January 18 to April 25 in 2020 were enrolled. They were divided into a metformin group and a none-metformin group according to whether the metformin was used. The demographic characteristics, clinical symptoms, laboratory parameters, treatment and clinical outcomes of the two groups were analyzed retrospectively.ResultsThere were 29 patients in the metformin group, 3 patients (12.0%, 3/25) suffered myocardial injury and 1 (3.4%) died of acute respiratory failure complicated by septic shock; 67 patients were in the non-metformin group and 24 (37.5%, 24/64) had myocardial injury but 15 died in hospital among whom 1 died of septic shock complicated by disseminated intravascular coagulation, 1 acute respiratory failure complicated by possible cerebral hemorrhage, 2 acute respiratory failure, 1 fulminant myocarditis, 3 acute myocardial infarction and 7 cardiac arrest. The incidence of myocardial injury (12.0% vs. 37.5%, P=0.019), hospital mortality (3.4% vs. 22.4%, P=0.034) and mortality of cardiovascular events (0.0% vs. 16.4%, P=0.049) in the metformin group were significantly lower than those in the non-metformin group. Multivariate analysis showed that the use of insulins (OR=11.235, P=0.003) was an influencing factor for in-hospital mortality of patients. The use of metformin (OR=0.154, P=0.013) was positively correlated with the myocardial injury.ConclusionWhen patients with coronary heart disease and diabetes are infected with COVID-19, metformin can effectively reduce myocardial damage and has a certain effect on reducing hospital mortality. Combined with clinical considerations, it is worthy of popularization.

    Release date:2021-04-25 09:57 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content